SquareMind raises $18 million to commercialize Swan, a robotic platform for standardized skin imaging in dermatology

SquareMind announced $18 million in funding led by Sonder Capital, with participation from the Deeptech 2030 Fund, Adamed Technology, Calm/Storm Ventures, Teampact Ventures, and several entrepreneurs. The round includes previously undisclosed pre-Series A financing.

Swan is a robotic system that captures full-body dermoscopic skin imaging (standardized images obtained from close examination of moles) in minutes through an automated, contactless process. It pairs with AI-based software to help track new or changing moles while physicians retain clinical judgment.

The funding will support commercial, engineering, and customer support teams ahead of a near-term launch in the United States and Europe. Skin screening is the number-one volume procedure in dermatology, with demand outpacing capacity due to a rapidly aging population; 80 percent of melanomas are new lesions, making thorough documentation important for early detection.